The LAG-3 next-generation immunotherapies market is projected to grow from $463.6 million in 2024 to $5.5 billion by 2035, driven by increasing solid tumor cases and expanding treatment options.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.